Department of Paediatrics, Haematology, Oncology and Endocrinology, Medical University of Gdansk, 7 Debinki Street, 80-211, Gdansk, Poland.
J Cancer Res Clin Oncol. 2010 Feb;136(2):293-305. doi: 10.1007/s00432-009-0661-x. Epub 2009 Aug 20.
To establish the clinical utility of serum soluble IL-2 receptor (sIL-2R alpha), lactate dehydrogenase (LDH) [corrected] and B2-microglobulin [corrected] (B2-M) as markers for diagnosis, prognosis and treatment monitoring in childhood soft tissue sarcomas (STS).
The markers[corrected] were measured prospectively before treatment, in complete remission (CR) during and after therapy and at relapse [corrected] in 35 children with STS and in 50 healthy children [corrected] (once).
Serum sIL-2R alpha and LDH [corrected] correlated with age thus they were [corrected] presented as multiplications [corrected] of the upper normal ranges [corrected] for age. Pre-treatment levels [corrected] of sIL-2R alpha and LDH [corrected] but not of B2-M exceeded significantly those of controls. [corrected] Elevated [corrected] sIL-2R alpha levels correlated with more [corrected] advanced stages, poor-risk histology and poor response to chemotherapy, higher LDH with incomplete primary tumour [corrected] resection and increased B2-M with poor-risk histology. [corrected] Patients' age >10 years, male gender and unfavourable tumour localisation were not accompanied by the markers' elevation. [corrected] None of the markers predicted EFS and OS. [corrected] Good response to chemotherapy was paralleled by significant decline of sIL-2R alpha and LDH pre-treatment levels while relapse--by sIL-2R alpha and LDH increase to values similar to those at diagnosis. [corrected] Monitoring of B2-M did not reflect the disease course. [corrected]
sIL-2R alpha and LDH were [corrected] proven to be promising markers [corrected] for diagnosis and treatment monitoring in children with STS. The markers [corrected] correlated also with some [corrected] important prognostic clinico-pathological factors for childhood [corrected] STS; however, they [corrected] failed to predict EFS and OS. Measurements of serum [corrected] B2-M were shown [corrected] to have no clinical value in the diagnostics, prognostics and treatment monitoring in paediatric STS.
确定血清可溶性白细胞介素 2 受体（sIL-2Rα）、乳酸脱氢酶（LDH）[已更正]和β2-微球蛋白（B2-M）作为儿童软组织肉瘤（STS）诊断、预后和治疗监测标志物的临床实用性。
在 35 名 STS 患儿治疗前、完全缓解（CR）期间和治疗后以及复发时[已更正]以及 50 名健康儿童[已更正]（一次）前瞻性测量了这些标志物[已更正]。
血清 sIL-2Rα和 LDH [已更正]与年龄相关，因此它们[已更正]表示为年龄正常上限[已更正]的倍数。治疗前 sIL-2Rα和 LDH [已更正]水平显著高于对照组。[已更正]升高的[已更正]sIL-2Rα水平与更晚期、高危组织学和对化疗反应差、不完全原发性肿瘤[已更正]切除与较高的 LDH 以及高危组织学与增加的 B2-M 相关。[已更正]患儿年龄>10 岁、男性和不利的肿瘤定位不伴有标志物升高。[已更正]没有标志物预测 EFS 和 OS。[已更正]化疗反应良好与 sIL-2Rα和 LDH 治疗前水平显著下降平行，而复发则与 sIL-2Rα和 LDH 升高至与诊断时相似的水平有关。[已更正]B2-M 的监测未反映疾病过程。[已更正]
sIL-2Rα和 LDH[已更正]被证明是儿童 STS 诊断和治疗监测有前途的标志物[已更正]。这些标志物[已更正]还与儿童 STS 的一些[已更正]重要预后临床病理因素相关；然而，它们[已更正]未能预测 EFS 和 OS。在儿科 STS 的诊断、预后和治疗监测中，血清[已更正]B2-M 的测量显示[已更正]没有临床价值。
